The high retail cost of Vascepa is primarily attributed to the extensive research, complex clinical trials, and specialized manufacturing processes required to produce high-purity icosapent ethyl. Developing the drug and securing expanded cardiovascular risk-reduction indications through massive multi-year clinical studies involved hundreds of millions of dollars in capital investment. Additionally, the patented multi-month purification process necessary to remove impurities and prevent active ingredient oxidation commands specialized technical overhead. Brand-name patent protections and the costs associated with regulatory compliance also influence market pricing prior to the widespread availability of generic alternatives.